BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//Catalyst Brief//FDA catalyst calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Catalyst Brief — FDA catalyst calendar
REFRESH-INTERVAL;VALUE=DURATION:PT6H
X-PUBLISHED-TTL:PT6H
BEGIN:VEVENT
UID:event-19@catalystbrief.girapphe.com
DTSTAMP:20261117T061546Z
LAST-MODIFIED:20261117T061546Z
DTSTART;VALUE=DATE:20270301
DTEND;VALUE=DATE:20270302
SUMMARY:Readout: Seattle Project Corporation — GRT-C901 [Mar 2027]
DESCRIPTION:Phase 3 primary completion: A Study of a Patient-Specific Neoan
 tigen Vaccine in Combination With Immune Checkpoint Blockade for Patients 
 With Metastatic Colorectal Cancer.\nSource: https://clinicaltrials.gov/stu
 dy/NCT05141721\nhttps://catalystbrief.girapphe.com/e/19?lang=en\nNot inves
 tment advice. Dates may change.
URL:https://catalystbrief.girapphe.com/e/19?lang=en
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
